Targeted Genetics Corp /WA/ - Current report filing (8-K)
28 4월 2008 - 7:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported):
April
23, 2008
Targeted
Genetics Corporation
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Washington
|
|
0-23930
|
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
|
98101
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
|
(206) 623-7612
|
Not
Applicable
(Former
name or former address if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On
April 23, 2008, Targeted Genetics received a staff deficiency letter from the
Nasdaq Stock Market informing Targeted Genetics that for the last 30 consecutive
business days, the bid price of Targeted Genetics’ common stock has closed below
the minimum $1.00 per share requirement for continued listing under Marketplace
Rule 4310(c)(4).
The
letter stated that under Marketplace Rule 4310(c)(8)(d), Targeted Genetics
will be provided with 180 calendar days, or until October 20, 2008, to regain
compliance with Marketplace Rule 4310(c)(4). To regain compliance, anytime
before October 20, 2008, the bid price of Targeted Genetics’ common stock must
close at $1.00 per share or more for a minimum of 10 consecutive business days.
On
October 20, 2008, if Targeted Genetics meets The Nasdaq Capital Market initial
inclusion criteria set forth in Marketplace Rule 4310(c), except for the
bid price requirement, it may be provided with an additional 180 calendar day
compliance period to demonstrate compliance. If Targeted Genetics is not
eligible for an additional compliance period at that time, Nasdaq Staff will
provide written notification that Targeted Genetics’ securities will be
delisted. Upon such notice, Targeted Genetics may appeal the Nasdaq Staff’s
Determination to a Listing Qualifications Panel, pursuant to the procedures
set
forth in the Nasdaq Marketplace Rule 4800 Series. There can be no assurance
that, if Targeted Genetics does appeal the Nasdaq Staff’s Determination that
such appeal would be successful.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
TARGETED
GENETICS CORPORATION
|
|
|
|
Dated:
April 25, 2008
|
By:
|
/s/
David J. Poston
|
|
David
J. Poston
Vice
President Finance and Chief Financial
Officer
|
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024